Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants

KRAS is the most frequently mutated oncogene, harboring mutations in approximately one in seven cancers. Allele-specific KRAS(G12C) inhibitors are currently changing the treatment paradigm for patients with KRAS(G12C)-mutated non–small cell lung cancer and colorectal cancer. The success of addressin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofmann, Marco H., Gerlach, Daniel, Misale, Sandra, Petronczki, Mark, Kraut, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394389/
https://www.ncbi.nlm.nih.gov/pubmed/35046095
http://dx.doi.org/10.1158/2159-8290.CD-21-1331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394389/
https://www.ncbi.nlm.nih.gov/pubmed/35046095
http://dx.doi.org/10.1158/2159-8290.CD-21-1331

Ejemplares similares